



CrossMark  
click for updates

Cite this: *Chem. Sci.*, 2017, 8, 499

# Copper carbenes alkylate guanine chemoselectively through a substrate directed reaction†

Stefanie N. Geigle,<sup>a</sup> Laura A. Wyss,<sup>b</sup> Shana J. Sturla<sup>b</sup> and Dennis G. Gillingham<sup>a</sup>

Cu(I) carbenes derived from  $\alpha$ -diazocarbonyl compounds lead to selective alkylation of the O<sup>6</sup> position in guanine (O<sup>6</sup>-G) in mono- and oligonucleotides. Only purine-type lactam oxygens are targeted – other types of amides or lactams are poorly reactive under conditions that give smooth alkylation of guanine. Mechanistic studies point to N7G as a directing group that controls selectivity. Given the importance of O<sup>6</sup>-G adducts in biology and biotechnology we expect that Cu(I)-catalyzed O<sup>6</sup>-G alkylation will be a broadly used synthetic tool. While the propensity for transition metals to increase redox damage is well-appreciated, our results suggest that transition metals might also increase the vulnerability of nucleic acids to alkylation damage.

Received 5th August 2016  
Accepted 2nd September 2016

DOI: 10.1039/c6sc03502g

www.rsc.org/chemicalscience


## Introduction

Catalytic reactions with metal carbenes are broadly applied in synthetic chemistry.<sup>1,2</sup> Although metal carbenes are reactive intermediates, their chemoselectivity can be steered through the right combination of metal, ligand, and carbene precursor.<sup>3</sup> Even in water metal carbenes can still perform an impressive array of transformations.<sup>4–7</sup> In our studies on the post-synthetic tailoring of large nucleic acids through metal catalysis we have found that donor–acceptor substituted carbenes<sup>8</sup> derived from Rh(II) and Cu(I) give primarily N–H insertion of exocyclic amine groups in unpaired regions of DNAs and RNAs.<sup>9–11</sup> Here we show that unstabilized Cu(I) carbenes derived from  $\alpha$ -diazo acetate and amide derivatives have a completely different chemoselectivity: they quickly and cleanly alkylate the O<sup>6</sup> position in guanine and inosine (see Fig. 1B for a representative reaction with GMP and ethyl  $\alpha$ -diazoacetate (EDA)). Cu(I) is known to bind amides (especially amidates),<sup>12</sup> but there is no precedence which would have predicted such a pronounced selectivity for the lactam-like oxygen of guanine. While most instances of copper<sup>13</sup> direction by heterocycles in synthetic chemistry<sup>14–16</sup> and biology<sup>17,18</sup> employ histidine or pyridine (see Fig. 1A), our results show that the purine ring system of guanine is also a powerful directing group in copper catalysed alkylation (see Fig. 1B) reactions.

DNA is constantly exposed to electrophiles, both natural and man-made.<sup>19</sup> In response, all organisms have evolved

DNA surveillance and repair pathways to maintain genomic integrity.<sup>20</sup> Alkylation at the O<sup>6</sup> of guanine<sup>21</sup> is particularly dangerous because polymerases tend to misincorporate thymidines in response to O<sup>6</sup>-(alkyl)-G during replication, leading to

### A Heterocycles direct copper in chemistry and biology



### B Here we find that N7G coordination leads copper carbenes to alkylate the O<sup>6</sup> position in guanine




Fig. 1 (A) In both synthetic chemistry and biology there are numerous examples of copper chemistry being controlled by coordination to nitrogen heterocycles (PDB ID: 1YEW) (B) N7 of guanines and inosines can direct copper catalysed reactions to the O<sup>6</sup> position.

<sup>a</sup>Department of Chemistry, University of Basel, St. Johannis-Ring 19, CH-4056, Basel, Switzerland. E-mail: dennis.gillingham@unibas.ch

<sup>b</sup>Department of Health Sciences and Technology, ETH Zurich, Schmelzbergstrasse 9, CH-8092 Zurich, Switzerland

† Electronic supplementary information (ESI) available: For complete experimental details and characterization data. See DOI: 10.1039/c6sc03502g



potentially carcinogenic G-to-A transition mutations.<sup>22–25</sup> The colon cells of people on high red meat diets have increased carboxymethyl damage at O<sup>6</sup>-G.<sup>26,27</sup> Epidemiological studies have shown that the high-red meat diet demographic in Western cultures suffer as well from a higher prevalence of gastrointestinal cancers.<sup>28,29</sup> Whether there is a causative connection between these two occurrences is currently unclear. Studying the biology of O<sup>6</sup>-(carboxymethyl)-G damage (O<sup>6</sup>-cmG), however, is hampered by synthetic challenges. Multi-step procedures, protecting group manipulations,<sup>30</sup> and the need for strong electrophilic phosphorous reagents,<sup>31</sup> combine to make both the synthesis and purification of O<sup>6</sup>-(alkyl)-G derivatives laborious. With copper catalysed alkylation the carboxymethyl motif is introduced in a single step from naturally occurring precursors.

## Results and discussion


### Reaction discovery and substrate scope

Cu(I) carbenes derived from  $\alpha$ -diazocarbonyl compounds are highly selective for O<sup>6</sup> alkylation of unpaired guanines and inosines in ssDNA, monophosphates (MP) and triphosphates (TP) (see Fig. 1B and Table 1). The surprising selectivity prompted us to synthesize an O<sup>6</sup>-alkyl-inosine adduct by

traditional routes to check the site-selectivity: identical characterization data confirm the proposed structures (see the ESI,† page S5–6). The method is the most concise and selective approach ever reported to the O<sup>6</sup>-(alkyl)-G motif and it is post-synthetic, obviating the need for solid phase DNA synthesis with modified phosphoramidites. The convergent assembly opens the door to a range of O<sup>6</sup>-(alkyl)-G derivatives from simple starting materials.

We explored the efficiency and selectivity of O<sup>6</sup>-G targeting by characterizing reactions with nucleotide monophosphates. Treatment of dGMP or GMP with 20 mol% Cu(II)SO<sub>4</sub> (*in situ* reduced by ascorbate) and ethyl  $\alpha$ -diazooacetate (EDA) in aqueous buffer resulted in high conversion and isolated yields of ethylcarboxymethyl product (see Table 1, entry 1 and 2) within 30 min. Under the same conditions, the structural analogues IMP, GTP, and dGTP were efficiently alkylated at their O<sup>6</sup> positions (see Table 1, entry 6, 11 and 12). In contrast, reactions without catalyst (entry 5) or with different MPs like UMP, AMP, CMP, or TMP (entries 7–10) resulted in little or no detectable alkylation. Rather, in cases where substrates lacked a guanine, the starting material was partially converted through unselective pathways that we could not completely characterize – in each case some alkylation was usually observed in the MS but these did not give substantial HPLC peaks that we could isolate. The same was also seen in short DNA fragments such as d(TAT) (see entry 14); here again starting material was consumed over time, but no single alkylation product could be isolated. In contrast, when guanine was present post-synthetic modifications of a DNA 3-mer d(TGT) and 9-mer d(TTTGTGTTT) with the EDA-derived Cu(I) carbene gave a single large alkylation product (only O<sup>6</sup>-G alkylation observed, see Table 1 entries 13 and 17). In the substrates that lack guanine we cannot account for the mass balance: we believe in these cases that oxidation is a side-reaction that consumes starting material when no guanine is available for the carbene-based reaction.

**Table 1** Reactions of ethyl  $\alpha$ -diazooacetate (EDA) with mono- and oligonucleotides



Entry	Substrate	Time (min)	Cosolvent	Conv. (%)	Yield. (%)
1 <sup>a</sup>	dGMP	30	None	98 <sup>e</sup>	86
2 <sup>a</sup>	GMP	30	None	96 <sup>e</sup>	92
3 <sup>b</sup>	GMP	30	DMSO	93 <sup>e</sup>	—
4 <sup>c</sup>	GMP	30	None	87 (ref. 32)	—
5 <sup>d</sup>	GMP	150	None	0	—
6 <sup>a</sup>	IMP	30	None	92 <sup>e</sup>	81
7 <sup>a</sup>	AMP	30	None	40	—
8 <sup>a</sup>	CMP	30	None	38	—
9 <sup>a</sup>	UMP	30	None	21	—
10 <sup>a</sup>	TMP	30	None	13	—
11 <sup>b</sup>	GTP	30	<i>t</i> BuOH	98 <sup>e</sup>	73
12 <sup>b</sup>	dGTP	30	<i>t</i> BuOH	97 <sup>e</sup>	65
13 <sup>a</sup>	d(TGT)	15/45	None	62/81 <sup>e</sup>	—
14 <sup>a</sup>	d(TAT)	120	None	35 <sup>f</sup>	—
15 <sup>b</sup>	d(ATGC)	150	<i>t</i> BuOH	38 <sup>e</sup>	—
16 <sup>b</sup>	d(ATGC)	150	Dioxane	64 <sup>e</sup>	—
17 <sup>b</sup>	d(TTTGTGTTT)	30	DMSO	82 <sup>e</sup>	—

<sup>a</sup> Complete conditions: 5 mM substrate, 1 mM CuSO<sub>4</sub>, 5 mM ascorbate, 50 mM EDA (ethyl diazoacetate), 100 mM MES (2-(*N*-morpholino) ethanesulfonic acid) pH 6, H<sub>2</sub>O, 25 °C. <sup>b</sup> Same conditions as <sup>a</sup> but with 20% (v/v) of cosolvent. <sup>c</sup> No ascorbate added. <sup>d</sup> No CuSO<sub>4</sub> or ascorbate added. <sup>e</sup> Alkylation site was assigned on the basis of tandem MS fragmentation ions. <sup>f</sup> Six minor mono-alkylation products were detected by ESI, but none in an amount that could be isolated.


### Cosolvent, oligonucleotide size, and diazo substrate all modulate reactivity











While oligonucleotides also reacted selectively at O<sup>6</sup>-G, the reactions were slower. For example, d(ATGC) was alkylated at O<sup>6</sup>-G (determined by MS-MS sequencing, see ESI page S18†) but required longer reaction times and conversion was lower than for the mononucleotides (*cf.* Table 1 entries 11 & 15). This reduced reactivity can likely be attributed to the unproductive sequestration of copper to other binding sites (phosphate backbone, other nucleobases) in the nucleic acid. The lower reactivity with longer oligonucleotides was mitigated by using 1,4-dioxane as a cosolvent. For example, changing the stock solution of EDA from 10% *t*BuOH in water to dioxane nearly doubled the conversion of d(ATGC) (*cf.* Table 1 entries 15 & 16). Nevertheless, these observations point to a limitation of the method: the larger the oligonucleotide the slower it is likely to react.

Diazo substrate variation is another approach to improve the reaction with challenging nucleic acid substrates. Diazoacetamides<sup>33</sup> (DAAs) led to higher conversions than EDA and high O<sup>6</sup> selectivity was maintained (see Table 2). For example,



Table 2 Reactions of diazo acetamides (DAAs) with oligonucleotides



Entry	Substrate	Diazo compound	Time (min)	Conv. (%)
1	d(TGT)		15	78 <sup>b</sup>
2	d(TGT)		15	78 <sup>b</sup>
3	d(ATGC)		150	62 <sup>b</sup>
4	d(ATGC) <sup>c</sup>		30	74 <sup>b</sup>
5	d(ATGC)		150	61 <sup>b</sup>
6	d(TTTTGTTTT)		30	92 <sup>b</sup>
7	d(TTTTGTTTT)		30	81 <sup>b</sup>
8	d(AACAGTCATATCCTTA)		180	48
9	d(AACAGTCATATCCTTA)		180	40
10	d(ATGC) <sup>c</sup>		150	66 <sup>b</sup>

<sup>a</sup> Complete conditions: 5 mM substrate, 1 mM CuSO<sub>4</sub>, 5 mM ascorbate, 50 mM diazo compound, 100 mM MES pH 6, DMSO 20% (v/v), H<sub>2</sub>O, 25 °C.

<sup>b</sup> G-alkylation was assigned on the basis of tandem MS fragmentation ions. <sup>c</sup> Same conditions as *a* but with 20% (v/v) dioxane instead of DMSO.

the alkylation of d(ATGC) with DAAs led to conversions of starting material above 60% (see entries 3 & 5, Table 2), whereas the same substrate with EDA led to only 38% conversion (see entry 15, Table 1). While DAAs are better substrates in nucleic acid alkylation, they are also less stable; it was, for example, impossible to prepare a stock solution in 10% *t*BuOH and water due to rapid decomposition. DMSO as co-solvent stabilizes the DAAs, with the drawback that their reactivity in nucleic acid alkylation is reduced. Changing to a less coordinating co-solvent like dioxane seems to be the best compromise between these competing effects. For example comparing entries 3 & 4 in Table 2 we see that in 20% dioxane higher conversion was obtained in a fifth of the time (62% after 150 minutes *versus* 74% after 30 minutes). With the more reactive DAAs, even longer

DNAs such as 16-mers were alkylated efficiently (see entries 8 & 9, Table 2). The amide substrates offer the additional advantages of stability and modularity. Customization of substrates for pull-downs or with fluorescent tags would simply require the addition of the appropriate amine in the DAA synthesis.<sup>33</sup> As an example, modification of guanine at the O<sup>6</sup> position of d(ATGC) with a terminal alkyne-bearing diazo substrate (see entry 10, Table 2) followed by a click reaction with azide-conjugated biotin (see the ESI page S31†), installed a complex pull-down tag in only two steps.

### Mechanistic hypothesis

The selectivity observed with copper carbenes does not reflect the intrinsic nucleophilicity of DNA nucleophiles.<sup>34</sup> In studies



with powerful alkylating agents, it has been established that N7G is the most potent nucleophile in both dsDNA and ssDNA. O<sup>6</sup>-G alkylation is found five to tenfold less, while the remaining heteroatoms account for approximately five percent of alkylation products.<sup>21</sup> Since unstabilized Cu(I) carbenes should be highly reactive with water, we expected that the selectivity might stem from pre-association of copper with the guanine nucleobase. Guanine is the most electron rich of the nucleobases and readily chelates with divalent metals, including copper(II).<sup>35,36</sup> DFT calculations of molecular dipoles in DNA bases indicate that guanine has the largest molecular dipole (6.9 D) and its negative pole is located between O<sup>6</sup> and N7. On the other hand, little is known about the interaction of Cu(I) with DNA,<sup>37</sup> likely because the Cu(I) oxidation state has limited stability in aqueous buffer at neutral pH (it tends to oxidize or disproportionate)<sup>38</sup> and is therefore difficult to study. Nevertheless, based on analogy to Cu(II), which readily binds guanine N7s, we hypothesize that the selectivity derives from carbene formation with an N7 bound copper atom. Crystal structure data for Cu(II)<sup>39</sup> and other divalent metals<sup>36</sup> show a strong preference for N7G coordination, with a consequent positioning of the metal approximately 3.5 Å away from O<sup>6</sup>. The bound carbene would be thus poised to form a metal ylide with the O<sup>6</sup> position (see lower mechanistic scheme in Fig. 2), and an irreversible protonation would complete the alkylation.

The selectivity that we observe mirrors the preference in sites of Cu-catalysed oxidative (peroxide or superoxide) damage in DNA, which show increased oxidation at and around guanine residues.<sup>40</sup> The research on copper-mediated redox damage supports two main pathways. In the first an unbound copper(I) ion releases reactive oxygen species upon oxygen reduction or hydrogen peroxide cleavage, the resulting hydroxyl radical diffuses to the nearest site on DNA and typically leads to DNA fragmentation. This mechanism is unselective and presents a constant danger to DNA and RNA – it is, however, inefficient. In the second mechanism a guanine-bound copper(I) forms a copper(II) oxo complex by reacting with peroxide, leading to oxidative damage of the guanine itself as well as neighbouring bases. These reports on oxidative damage, however, provided no

insight on why guanine was the target or how the copper bound. We propose that both the specificity of oxidative damage observed in earlier reports and the alkylation specificity we observe here is a result of the same thing: guanine's superior ability to coordinate copper.

The hypothesis that guanine pre-coordination controls chemoselectivity would predict the following:

- (1) Other amide or lactone substrates that lack the strong coordination ability of guanine should be poorly reactive.
- (2) Strongly chelating multidentate ligands should be deleterious to reactivity, since the combination of the guanine and the multidentate ligand would not leave space in copper's coordination environment for carbene formation.

Over the next two sections we will examine experimental data for each of these scenarios and demonstrate that the hypothesis holds.

### 1. Normal amide or lactone substrates are poorly reactive.

The most compelling example for the importance of N7G coordination is the 7-deaza-2'-deoxyguanosinetriphosphate (deaza-dGTP), which shows substantially reduced reactivity and selectivity in comparison to normal guanine (see the HPLC traces in Fig. 3). The simple thymidine substrate as well as the cyclic lactam piperidin-2-one are similarly unreactive, adding further weight to the idea that the N7 coordination is the decisive factor in O<sup>6</sup> alkylation specificity. Although no literature precedence exists for this Cu(I)-based mechanism, a recent report has shown that histidine residues in proteins can control selectivity in the Cu(II)-catalysed alkenylation reaction of the amide backbone.<sup>16</sup>

### 2. Multidentate ligands inhibit and N-heterocyclic carbene (NHC) ligands promote guanine alkylation.

The copper-catalysed azide alkyne cycloaddition (CuAAC) is a widely used ligation reaction in chemical biology. Ligands such as bathocuproine and




Fig. 2 Mechanistic proposal accounting for the high O<sup>6</sup>-G chemoselectivity. Electrostatic potential map and the molecular dipole moment (6.9 D) were calculated in Spartan'14 with DFT calculations at the EDF2 6-31G\* level of theory using 9-methylguanine.




Fig. 3 Substrate-based mechanistic probes point to the role of the N7 of guanine in directing the chemoselectivity. Only the dGMP starting material leads to efficient reaction. HPLC traces were recorded after 30 min reaction time. Reaction conditions: 5 mM substrate (dGMP or deaza-dGTP or TMP or  $\alpha$ -valerolactone), 1 mM CuSO<sub>4</sub>, 5 mM ascorbate, 50 mM EDA, 100 mM MES pH 6, dioxane 20% (v/v), H<sub>2</sub>O, 25 °C.





tristriazoles are often used to stabilize Cu(I) and accelerate the reaction.<sup>41–43</sup> In our case, however, the addition of strongly coordinating ligands such as tris(3-hydroxypropyltriazolylmethyl) amine (THPTA) or bathocuproinedisulfonic acid disodium salt (BCA) lead to a suppression of guanine alkylation. Even after several hours little or no alkylation product could be detected (see Fig. 4A). In the case of THPTA the copper carbene was still formed (see disappearance of EDA in HPLC trace) but no guanine alkylation was observed. Instead the diazo compound is consumed in unproductive decomposition reactions.

A copper catalyst bearing an N-heterocyclic carbene (NHC) ligand behaved differently: mesitylimidazolium copper chloride (MesCuCl) gave the same alkylation profile as the standard 'ligandless' conditions, with O<sup>6</sup>-G alkylation being the dominant product (see Fig. 4B). It is revealing that the NHC ligand, which is not bidentate and hence would still allow coordination with N7G, is the only type tested that maintained alkylation activity. The NHC ligands have other favourable properties for the alkylation reaction (such as reducing oxidative damage) and we are currently exploring the full potential of NHC ligands in DNA and RNA alkylation.

### Biochemical studies with O<sup>6</sup>-(alkyl)-G adducts

With ready access to O<sup>6</sup>-G derivatives we next used the products to study two open questions in the biochemistry of O<sup>6</sup>-G adducts: first, their repair by alkylguanine transferases (AGTs) and second, their incorporation during DNA replication.

### Human AGT repairs peptide-like carboxamide adducts

AGTs are found in all domains of life and are responsible for repairing O<sup>6</sup>-G adducts in the genome. Human AGT (hAGT) repairs O<sup>6</sup>-(alkyl)-G adducts from single stranded and duplex DNAs.<sup>44–47</sup> The repair pathway is important since polymerases often mis-incorporate T when bypassing this lesion during replication.<sup>48,49</sup> Evolution has found no effective catalytic solution to the direct reversal of O<sup>6</sup>-G damage; instead AGT acts as a suicide protein. It bears a nucleophilic cysteine that attacks the alkyl group of the adduct and restores the native guanine.<sup>44</sup> Previous reports conflict as to whether carboxymethyl damage is repaired by hAGT.<sup>50,51</sup> In addition, since diazotized peptides are the likely source of these alkylation adducts,<sup>26,50</sup> it is important to understand whether adducts bearing amides are also effectively repaired. Bacteria also produce diazo peptide natural products that may alkylate DNA,<sup>52,53</sup> adding additional impetus to understand the repair of amide adducts. Thus, we tested whether a DNA 9-mer modified with a cyclohexyl carboxymethylamide (see Table 2, entry 6), was a substrate for hAGT (see Fig. 5). Although removal of the adduct was slow (reduced rates are expected for ssDNAs),<sup>54</sup> analysis of both the deoxyoligonucleotide (see panel B in Fig. 5) and the protein (see panel C in Fig. 5) indicate repair occurred. These results support the most recent claim that carboxymethyl adducts are indeed repaired,<sup>51</sup> and it adds the carboxymethyl amide motif to the list of deoxyoligonucleotides repaired by hAGT.




Fig. 4 (A) Multidentate ligands like THPTA and bathocuproine disulfonic acid disodium salt (BCA) suppress dGMP alkylation. (B) dGMP alkylation catalysed by MesCuCl is highly efficient. HPLC trace was recorded after 30 minutes reaction time.




Fig. 5 (A) De-alkylation of O<sup>6</sup>-G modified ssDNA 9 mer by hAGT at 37 °C. (B) HPLC analysis of the reaction mixture after 0 (green), 0.5 (purple) and 4 hours (red). (C) High resolution ESI-MS from hAGT after 4 h at 37 °C (the second set of peaks derive from a post-translational modification (likely methylation) of hAGT that we cannot identify, but which has no effect on its function since both masses shift after the dealkylation).

## O<sup>6</sup>-G alkylated triphosphates can be misincorporated during DNA synthesis

To test the impact of O<sup>6</sup>-alkylation on nucleotide incorporation during DNA synthesis, we characterized O<sup>6</sup>-(alkyl)-G triphosphates as polymerase substrates. Thus, we synthesized the modified deoxynucleotidetriphosphates O<sup>6</sup>-(ethyl carboxymethyl)-dGTP and (O<sup>6</sup>-(ethylcm)-dGTP) and O<sup>6</sup>-(carboxymethyl)-dGTP (O<sup>6</sup>-(cm)-dGTP) with our Cu(I) carbene methodology. Selective carboxymethylation of commercial dGTP at the O<sup>6</sup> position with EDA as carbene precursor directly delivers O<sup>6</sup>-(ethylcm)-dGTP and a subsequent ester hydrolysis yields O<sup>6</sup>-(cm)-dGTP; hence both molecules are obtained in a total of two chemical operations (see Fig. 6A). The direct modification approach offers unprecedented efficiency in the formation of O<sup>6</sup>-G adducts (in this case from a commercial triphosphate without any protecting group or phosphorylation steps). Previous syntheses of O<sup>6</sup>-G modified nucleosides and triphosphates involved four<sup>31</sup> to seven<sup>55–58</sup> steps including triphosphate introduction using strong electrophilic phosphorous reagents.<sup>59</sup>

To investigate the incorporation of O<sup>6</sup>-(cm)-dGTP and O<sup>6</sup>-(ethylcm)-dGTP during DNA synthesis, we performed single nucleotide primer extension experiments with *KTqM747K*, a mutant of KlenTaq polymerase that bypasses several DNA modifications.<sup>60–62</sup> Unmodified 28-mer templates (5'-ATT ATG CTG AGT GAT ATC CCT CTX CTC A) in which X = G, A, T or C

were annealed to a 5'-end [ $\gamma$ -<sup>32</sup>P] radiolabeled 23-mer primer (5'-AGA GGG ATA TCA CTC AGC ATA AT) and then subjected to primer extension conditions (see Fig. 6B). Reaction products were separated by denaturing polyacrylamide gel electrophoresis and visualized with phosphorimaging. Nucleotides O<sup>6</sup>-(cm)-dGTP as well as O<sup>6</sup>-(ethylcm)-dGTP were incorporated opposite both C and T, but C was especially well tolerated. Furthermore, whereas with T incorporation the polymerase stalls after the first extension, the O<sup>6</sup>-(alkyl)-G:C mismatch seems to pose no problem for the polymerase's procession since the second extension also occurs quickly (see the C lane in Fig. 6C). Consistent with steric matching as a key component in polymerase fidelity,<sup>63–66</sup> purine mismatches were poorly tolerated (see G and A bands in the gel in Fig. 6C). These experiments serve as the proof-of-concept that O<sup>6</sup>-(cm)-G damaged nucleotides can be incorporated during DNA replication. In light of these results a full study of how different polymerases (particularly human) deal with O<sup>6</sup>-(cm)-dGTP in the dNTP pool during replication is warranted.

## Conclusions

We have discovered a new way to create O<sup>6</sup>-G adducts post-synthetically in nucleic acids of varying size, from nucleotide mono- or triphosphates to long oligonucleotides. The ability to obtain high yields of precisely defined O<sup>6</sup>-G adducts eliminates a major roadblock in studying their biochemistry, a point we have illustrated through the first synthesis of O<sup>6</sup>-(cm)-dGTP and the first demonstration of its incorporation during DNA replication.

Copper-catalysed O<sup>6</sup>-G alkylation is a dump-and-stir procedure that employs readily available materials.  $\alpha$ -Dialko ester substrates are stable enough that several are sold commercially and a simple<sup>33</sup> two-step (one-pot) protocol for  $\alpha$ -dialko ester synthesis makes nearly any dialko compound in this class synthetically accessible. Research on O<sup>6</sup>-G adducts in biology<sup>67</sup> and biotechnology<sup>68</sup> demands ready synthetic access to these adducts and the method we have described is the simplest to date.

Nucleic acids are found in diverse contexts and can fold in myriad ways, complicating attempts at broad generalizations of reactivity. Nevertheless, the weight of evidence suggests N7G is the most powerful nucleophile<sup>34</sup> and ligand<sup>36</sup> in DNA and RNA. It is a primary target of organic electrophiles,<sup>34</sup> as well as organometallic anticancer drugs.<sup>69</sup> To the list of N7G's functions we add the role of directing group in copper catalysed reactions. We have focussed on alkylation reactions, but the same effect is likely responsible for the well-known propensity of Fenton-type oxidative damage to be localized around guanines.<sup>40</sup>

## Acknowledgements

D.G.G and S.N.G acknowledges the Swiss National Science Foundation (SNF) for financial support (grant number 200021\_149805). L.A.W and S.J.S acknowledge the European Research Council (260341), the SNF (156280), and the ETH




Fig. 6 (A) Synthesis of O<sup>6</sup>-(alkyl)-dGTPs with a Cu(I) carbene derived from EDA. (B) Single nucleotide primer extension with O<sup>6</sup>-(alkyl)-dGTPs opposite DNA templates G, A, T, and C catalyzed by *KTqM747K*. Reactions were performed at 55 °C for 10 min and contained 50  $\mu$ M dNTPs. (C) PAGE analysis of the primer extension experiment. M, blank corresponding to 23 nt primer.



research commission (ETH-43 14-1) for financial support. Prof. Nathan Leudtke and Mr Aaron Johnson are gratefully acknowledged for helpful discussions.

## Notes and references

- 1 M. A. M. M. P. Doyle and T. Ye, *Modern Catalytic Methods for Organic Synthesis with Diazo Compounds*, Wiley, New York, 1998.
- 2 A. Ford, H. Miel, A. Ring, C. N. Slattery, A. R. Maguire and M. A. McKervey, *Chem. Rev.*, 2015, **115**, 9981–10080.
- 3 D. Gillingham and N. Fei, *Chem. Soc. Rev.*, 2013, **42**, 4918–4931.
- 4 I. Nicolas, P. Le Maux and G. Simonneaux, *Coord. Chem. Rev.*, 2008, **252**, 727–735.
- 5 J. M. Antos and M. B. Francis, *J. Am. Chem. Soc.*, 2004, **126**, 10256–10257.
- 6 B. V. Popp and Z. T. Ball, *Chem. Sci.*, 2011, **2**, 690–695.
- 7 F. Vohidov, J. M. Coughlin and Z. T. Ball, *Angew. Chem., Int. Ed. Engl.*, 2015, **54**, 4587–4591.
- 8 H. M. L. Davies and D. Morton, *Chem. Soc. Rev.*, 2011, **40**, 1857–1869.
- 9 K. Tishinov, K. Schmidt, D. Haussinger and D. G. Gillingham, *Angew. Chem., Int. Ed.*, 2012, **51**, 12000–12004.
- 10 K. Tishinov, N. Fei and D. Gillingham, *Chem. Sci.*, 2013, **4**, 4401–4406.
- 11 N. Fei, D. Haussinger, S. Blumli, B.-J. Laventie, L. D. Bizzini, K. Zimmermann, U. Jenal and D. Gillingham, *Chem. Commun.*, 2014, **50**, 8499–8502.
- 12 G. Rousseau and B. Breit, *Angew. Chem., Int. Ed.*, 2011, **50**, 2450–2494.
- 13 E. I. Solomon, D. E. Heppner, E. M. Johnston, J. W. Ginsbach, J. Cirera, M. Qayyum, M. T. Kieber-Emmons, C. H. Kjaergaard, R. G. Hadt and L. Tian, *Chem. Rev.*, 2014, **114**, 3659–3853.
- 14 B. Schönecker, T. Zheldakova, Y. Liu, M. Köttleritzsch, W. Günther and H. Görls, *Angew. Chem., Int. Ed.*, 2003, **42**, 3240–3244.
- 15 Y. Y. See, A. T. Herrmann, Y. Aihara and P. S. Baran, *J. Am. Chem. Soc.*, 2015, **137**, 13776–13779.
- 16 J. Ohata, M. B. Minus, M. E. Abernathy and Z. T. Ball, *J. Am. Chem. Soc.*, 2016, **138**, 7472–7475.
- 17 K. A. Magnus, B. Hazes, H. Ton-That, C. Bonaventura, J. Bonaventura and W. G. Hol, *Proteins*, 1994, **19**, 302–309.
- 18 R. Balasubramanian, S. M. Smith, S. Rawat, L. A. Yatsunyk, T. L. Stemmler and A. C. Rosenzweig, *Nature*, 2010, **465**, 115–119.
- 19 F. Drablos, E. Feyzi, P. A. Aas, C. B. Vaagbø, B. Kavli, M. S. Bratlie, J. Peña-Díaz, M. Otterlei, G. Slupphaug and H. E. Krokan, *DNA Repair*, 2004, **3**, 1389–1407.
- 20 Nobel Media AB 2014, [http://www.nobelprize.org/nobel\\_prizes/chemistry/laureates/2015/press.html](http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2015/press.html), 2015.
- 21 We use the convention that exocyclic heteroatoms are labelled with a superscript and endocyclic ones with normal font: E. C. Friedberg, G. C. Walker, W. Siede and R. D. Wood, *DNA repair and mutagenesis*, American Society for Microbiology Press, 2005.
- 22 C. Coulondre and J. H. Miller, *J. Mol. Biol.*, 1977, **117**, 577–606.
- 23 M. Sekiguchi and K. Sakumi, *Jpn. J. Hum. Genet.*, 1997, **42**, 389–399.
- 24 G. P. Margison, M. F. Santibáñez Koref and A. C. Povey, *Mutagenesis*, 2002, **17**, 483–487.
- 25 F. Zhang, M. Tsunoda, K. Suzuki, Y. Kikuchi, O. Wilkinson, C. L. Millington, G. P. Margison, D. M. Williams, C. E. Morishita and A. Takenaka, *Nucleic Acids Res.*, 2013, **41**, 5524–5532.
- 26 B. C. Cupid, Z. Zeng, R. Singh and D. E. G. Shuker, *Chem. Res. Toxicol.*, 2004, **17**, 294–300.
- 27 M. H. Lewin, N. Bailey, T. Bandaletova, R. Bowman, A. J. Cross, J. Pollock, D. E. Shuker and S. A. Bingham, *Cancer Res.*, 2006, **66**, 1859–1865.
- 28 H. zur Hausen, *Int. J. Cancer*, 2012, **130**, 2475–2483.
- 29 V. Bouvard, D. Loomis, K. Z. Guyton, Y. Grosse, F. E. Ghissassi, L. Benbrahim-Tallaa, N. Guha, H. Mattock and K. Straif, *Lancet Oncol.*, 2015, **16**, 1599–1600.
- 30 Y.-Z. Xu, *Tetrahedron*, 2000, **56**, 6075–6081.
- 31 J. von Watzdorf, K. Leitner and A. Marx, *Angew. Chem., Int. Ed.*, 2016, **55**, 3229–3232.
- 32 R. G. Salomon and J. K. Kochi, *J. Am. Chem. Soc.*, 1973, **95**, 3300–3310.
- 33 T. Toma, J. Shimokawa and T. Fukuyama, *Org. Lett.*, 2007, **9**, 3195–3197.
- 34 D. Gillingham, S. Geigle and O. A. von Lilienfeld, *Chem. Soc. Rev.*, 2016, **45**, 2637–2655.
- 35 S. L. Labiuk, L. T. J. Delbaere and J. S. Lee, *J. Biol. Inorg. Chem.*, 2003, **8**, 715–720.
- 36 Y.-G. Gao, M. Sriram and A. H.-J. Wang, *Nucleic Acids Res.*, 1993, **21**, 4093–4101.
- 37 W. A. Prütz, J. Butler and E. J. Land, *Int. J. Radiat. Biol.*, 1990, **58**, 215–234.
- 38 D. K. Johnson, M. J. Stevenson, Z. A. Almadidy, S. E. Jenkins, D. E. Wilcox and N. E. Grossoehme, *Dalton Trans.*, 2015, **44**, 16494–16505.
- 39 B. H. Geierstanger, T. F. Kagawa, S. L. Chen, G. J. Quigley and P. S. Ho, *J. Biol. Chem.*, 1991, **266**, 20185–20191.
- 40 S. Oikawa and S. Kawanishi, *Biochemistry*, 1996, **35**, 4584–4590.
- 41 V. Hong, S. I. Presolski, C. Ma and M. G. Finn, *Angew. Chem., Int. Ed.*, 2009, **48**, 9879–9883.
- 42 V. Hong, N. F. Steinmetz, M. Manchester and M. G. Finn, *Bioconjugate Chem.*, 2010, **21**, 1912–1916.
- 43 S. I. Presolski, V. Hong, S.-H. Cho and M. G. Finn, *J. Am. Chem. Soc.*, 2010, **132**, 14570–14576.
- 44 A. E. Pegg, *Mutat. Res., Rev. Mutat. Res.*, 2000, **462**, 83–100.
- 45 K. Bender, M. Federwisch, U. Loggen, P. Nehls and M. F. Rajewsky, *Nucleic Acids Res.*, 1996, **24**, 2087–2094.
- 46 L.-K. Liem, C.-W. Wong, A. Lim and B. F. L. Li, *J. Mol. Biol.*, 1993, **231**, 950–959.
- 47 J. J. Rasimas, S. R. Kar, A. E. Pegg and M. G. Fried, *J. Biol. Chem.*, 2007, **282**, 3357–3366.



- 48 E. M. Duguid, P. A. Rice and C. He, *J. Mol. Biol.*, 2005, **350**, 657–666.
- 49 Y. Mishina, E. Duguid and C. He, *Chem. Rev.*, 2006, **106**, 215–232.
- 50 D. E. G. Shuker and G. P. Margison, *Cancer Res.*, 1997, **57**, 366–369.
- 51 P. Senthong, C. L. Millington, O. J. Wilkinson, A. S. Marriott, A. J. Watson, O. Reamtong, C. E. Eyers, D. M. Williams, G. P. Margison and A. C. Povey, *Nucleic Acids Res.*, 2013, **41**, 3047–3055.
- 52 C. C. Nawrat and C. J. Moody, *Nat. Prod. Rep.*, 2011, **28**, 1426–1444.
- 53 Y. Katoh, M. Maekawa and Y. Sano, *Mutat. Res., Rev. Genet. Toxicol.*, 1995, **342**, 37–41.
- 54 D. Bhattacharyya, R. S. Foote, A. M. Boulden and S. Mitra, *Eur. J. Biochem.*, 1990, **193**, 337–343.
- 55 S. A. Moore and D. E. G. Shuker, *J. Labelled Compd. Radiopharm.*, 2011, **54**, 855–858.
- 56 K. Abdu, M. K. Aiertza, O. J. Wilkinson, J. A. Grasby, P. Senthong, A. C. Povey, G. P. Margison and D. M. Williams, *Chem. Commun.*, 2012, **48**, 11214–11216.
- 57 C. L. Millington, A. J. Watson, A. S. Marriott, G. P. Margison, A. C. Povey and D. M. Williams, *Nucleosides, Nucleotides Nucleic Acids*, 2012, **31**, 328–338.
- 58 T. Shibata, N. Glynn, T. B. H. McMurtry, R. S. McElhinney, G. P. Margison and D. M. Williams, *Nucleic Acids Res.*, 2006, **34**, 1884–1891.
- 59 M. Hollenstein, *Molecules*, 2012, **17**, 13569–13591.
- 60 C. Gloeckner, K. B. M. Sauter and A. Marx, *Angew. Chem., Int. Ed.*, 2007, **46**, 3115–3117.
- 61 S. Obeid, A. Schnur, C. Gloeckner, N. Blatter, W. Welte, K. Diederichs and A. Marx, *ChemBioChem*, 2011, **12**, 1574–1580.
- 62 L. A. Wyss, A. Nilforoushan, F. Eichenseher, U. Suter, N. Blatter, A. Marx and S. J. Sturla, *J. Am. Chem. Soc.*, 2015, **137**, 30–33.
- 63 E. T. Kool, *Acc. Chem. Res.*, 2002, **35**, 936–943.
- 64 H. O. Sintim and E. T. Kool, *Angew. Chem., Int. Ed.*, 2006, **45**, 1974–1979.
- 65 S. Ulrich and E. T. Kool, *Biochemistry*, 2011, **50**, 10343–10349.
- 66 I. Hirao, M. Kimoto and R. Yamashige, *Acc. Chem. Res.*, 2012, **45**, 2055–2065.
- 67 A. Pegg, *Chem. Res. Toxicol.*, 2011, **24**, 618–639.
- 68 A. Gautier, A. Juillerat, C. Heinis, I. R. Corrêa Jr, M. Kindermann, F. Beaufils and K. Johnsson, *Chem. Biol.*, 2008, **15**, 128–136.
- 69 P. M. Takahara, A. C. Rosenzweig, C. A. Frederick and S. J. Lippard, *Nature*, 1995, **377**, 649–652.

